Medindia

X

Syneron-Candela Launches new Breakthrough Products at the 22nd World Congress of Dermatology in Seoul, Korea to Provide Unprecedented Aesthetic Device Technology

Wednesday, May 25, 2011 General News J E 4
Advertisement

YOKNEAM, Israel, May 24, 2011 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, announced today during the opening of the World Congress of Dermatology the global launch of several new devices that confirm the company's continued efforts towards offering physicians and their patients best in class solutions for energy based aesthetic applications.

These new devices and their upgrades are being presented to international physicians for the first time at the Syneron-Candela booth during a medical meeting which takes place only once every four years and represents the premier global event for latest advancements in skin health organized under the auspices of the International League of Dermatological Societies.

"We are excited about the opportunity we have to share our latest innovations with the prominent scientific and medical professionals attending this meeting," said Louis P. Scafuri, Chief Executive Officer of Syneron. "The history of our company is steeped in science that offers results and is at the basis of the trust filled relationships we have developed with our medical partners over the years."

ePrime(TM)

This revolutionary facial treatment technology offers consumers with the best possible treatment option for improved skin volume, tightening, tone and elasticity. This minimally invasive aesthetic device can deliver deep into the dermis controlled amounts of Radio Frequency (RF) energy for dramatic improvements in skin appearance in just one single treatment. During the media panel, Henry Hin Lee Chan, MD, PhD - Hong Kong Dermatology and Laser Centre said that because this device "uniquely induces marked elastin, collagen and hyaluronic acid production, all naturally occurring substances that help define skin tone and texture, we are getting great improvement in facial skin treated by e-Prime. In addition, we are getting great feedback from clients on how thrilled they are by their natural and relaxed appearance and improved complexion."

GentleLASE(R) Pro

This is the company's latest and most advanced aesthetic laser. With this new device, physicians are able to treat much more than just unwanted hair as it also offers an opportunity to treat sun damaged skin, age spots, freckles and wrinkles. It is easy to use, cost effective, fast and provides unparalleled hair removal efficacy thanks to its delivery of the highest peak power in hair removal lasers. The enhanced versatility of this machine comes from various features including the variable pulse duration, possibility to choose between six different spot sizes, multiple hand pieces and light weight delivery systems that contribute to lower operator fatigue and greater treatment convenience.

On-going innovation

"Innovation is the main driver of our business. We are passionate about it and all the new ideas or improvements we bring to the market, are based on strong scientific data and our heavy investment in research and development," said Shimon Eckhouse, co-founder and Chairman of Syneron.

A clear illustration of Syneron's innovation and ability to bring new and exciting products and technology to the market are 3 products that have been launched just within the last 12 months - elure(TM), eMatrix(R) and CO2RE(TM).

elure is a revolutionary topical cosmetic for skin lightening which uses the proprietary patented natural enzyme, Melanozyme(TM). elure is the only skin whitening product in the world that lightens skin by decomposing melanin, the pigment that accumulates in the skin to cause a darkened or uneven skin tone. This unique mode of operation allows elure to create healthier, brighter and younger-looking skin in less than 30 days, with an excellent safety profile and very high tolerability.

eMatrix Sublative Rejuvenation(R) is the world's first bipolar RF technology for energy-based facial rejuvenation. Patient down time is minimal when adopting this treatment methodology thanks to the unique delivery of high-intensity dermal impact and minimal epidermal disruption. Physicians can comfortably use this device for all skin types and tones and in particular the darker skin colors that are often more difficult to treat.

CO2RE is a complete CO2 resurfacing system that offers physicians more choices and greater flexibility for meeting their individual practice needs. It includes a unique fusion fractional mode for treating superficial and deep skin layers simultaneously with precision control over the intensity pattern and depth of ablation.

All of Syneron's products are backed by scientific data which is regularly presented at high level medical meetings and conferences, highlighting the company's commitment to science. This unique combination of cutting edge science, life-enhancing clinical results and high level of trust within the global aesthetic community contributes to solidifying Syneron's leadership position in the Medical Aesthetic market.

About Syneron Medical Ltd.

In 2009, Syneron Medical Ltd. and Candela Corporation merged to create the global leader in the medical aesthetic devices market with both a short and long-term vision for developing this market. The strong financial base and aligned resources, allow this newly formed company to offer customers the broadest available product portfolio, the best global service organization and an expansive worldwide distribution network.

Media contacts:

Linda.pavy@bm.com - Tel. +33-141867626; Mobile: +33-607594395

sungeun.yoon@pharmaxogilvy.com -Tel. +82-2-513-1879; Mobile: +82-10-9322-2678

SOURCE Syneron-Candela

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
$10 Million Verdict Against Johnson & Johnson Unit...
S
PreXion, Inc. Names Visionary Industry Leader, Mot...